Education, Science, Technology, Innovation and Life
Open Access
Sign In

The clinical value of the systemic immune-inflammation index for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy

Download as PDF

DOI: 10.23977/tranc.2024.050102 | Downloads: 8 | Views: 371

Author(s)

Yang Xiang 1, Li Chen 1

Affiliation(s)

1 Department of Cardiothoracic Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

Corresponding Author

Li Chen

ABSTRACT

This study attempted to investigate the clinical value of systemic immune-inflammation index (SII) for Major Pathologic Response (MPR) in non‑small cell lung cancer(NSCLC) patients receiving neoadjuvant chemoimmunotherapy. A total of 56 non‑small cell lung cancer patients who were diagnosed and received neoadjuvant chemoimmunotherapy in the First Affiliated Hospital of Chongqing Medical University from April 2019 to April 2023 December 2023 were retrospectively analyzed,all patients were divided into the MPR group (35 cases) and No-MPR group (21 cases) according to their postoperative pathological results. The baseline neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-infammation index (SII) and clinicopathological variables were assessed for their association with MPR.The receiver operating characteristic (ROC) curve analysis and area under the ROC curve (AUC) values were used to evaluate the optimal cutoff values of the NLR,PLR and SII,and independent influencing factors of postoperative MPR were analyzed by binary logistic regression. Results indicated that NLR, PLR, and SII levels were significantly lower in the MPR group compared to those of the No-MPR group (P<0.05).The results of the ROC analysis showed that the area under the curve for the NLR,PLR and SII were 0.794,0.728and 0.838,respectively. Univariate Logistic regression analysis showed that the NLR, PLR, and SII level were significantly related to MPR (P<0.05).According to multivariate Logistic regression analysis,only SII level(OR=0.12,95%CI 0.02-0.17,P=0.019) was independent influence factors for MPR. In conclusion, NSCLC patients with low SII level (<947.6) are more likely to achieve MPR receiving neoadjuvant chemoimmunotherapy. It is likely to become a clinical monitoring index for the efficacy of neoadjuvant chemoimmunotherapy.

KEYWORDS

Non-small cell lung cancer; Neoadjuvant therapy; Major pathological response; systemic immune-inflammation index; clinical value

CITE THIS PAPER

Yang Xiang, Li Chen, The clinical value of the systemic immune-inflammation index for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy. Transactions on Cancer (2024) Vol. 5: 8-17. DOI: http://dx.doi.org/10.23977/tranc.2024.050102.

REFERENCES

[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries [J]. CA: A Cancer Journal for Clinicians, 2021, 71(3): 209-249.
[2] LIANG Y, WAKELEE H A. Adjuvant chemotherapy of completely resected early stage non-small cell lung cancer (NSCLC) [J]. Translational lung cancer research, 2013, 2(5): 403-410.
[3] URAMOTO H, TANAKA F. Recurrence after surgery in patients with NSCLC [J]. Translational lung cancer research, 2014, 3(4): 242-249.
[4] AKINBORO O, DREZNER N, AMATYA A, et al. US Food and Drug Administration Approval Summary: Nivolumab Plus Platinum-Doublet Chemotherapy for the Neoadjuvant Treatment of Patients With Resectable Non-Small-Cell Lung Cancer [J]. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 41(17): 3249-3259.
[5] FORDE P M, SPICER J, LU S, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer [J]. New England Journal of Medicine, 2022, 386(21): 1973-1985.
[6] KUNDU J K, SURH Y J. Inflammation: gearing the journey to cancer [J]. Mutation research, 2008, 659(1-2): 15-30.
[7] DHARMAPURI S, ÖZBEK U, LIN J Y, et al. Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti-PD-1 therapy [J]. Cancer medicine, 2020, 9(14): 4962-4970.
[8] JOMRICH G, PAIREDER M, KRISTO I, et al. High Systemic Immune-Inflammation Index is an Adverse Prognostic Factor for Patients With Gastroesophageal Adenocarcinoma [J]. Annals of Surgery, 2021, 273(3): 532-541.
[9] TACHINAMI H, TOMIHARA K, YAMADA S I, et al. Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with recurrent oral squamous cell carcinoma treated with nivolumab [J]. The British journal of oral & maxillofacial surgery, 2023, 61(4): 320-326.
[10] LIU J, LI S, ZHANG S, et al. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab [J]. Journal of clinical laboratory analysis, 2019, 33(8): e22964.
[11] PROVENCIO M, NADAL E, INSA A, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial [J]. The Lancet Oncology, 2020, 21(11): 1413-1422.
[12] SHU C A, GAINOR J F, AWAD M M, et al. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial [J]. The Lancet Oncology, 2020, 21(6): 786-795.
[13] CASCONE T, LEUNG C H, WEISSFERDT A, et al. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial [J]. Nature medicine, 2023, 29(3): 593-604.
[14] COUSSENS L M, WERB Z. Inflammation and cancer [J]. Nature, 2002, 420(6917): 860-867.
[15] JIANG M, PENG W, PU X, et al. Peripheral Blood Biomarkers Associated With Outcome in Non-small Cell Lung Cancer Patients Treated With Nivolumab and Durvalumab Monotherapy [J]. Frontiers in oncology, 2020, 10: 913.
[16] ROMANO F J, RONGA R, AMBROSIO F, et al. Neutrophil-to-Lymphocyte Ratio Is a Major Prognostic Factor in Non-small Cell Lung Carcinoma Patients Undergoing First Line Immunotherapy With Pembrolizumab [J]. Cancer diagnosis & prognosis, 2023, 3(1): 44-52.
[17] ANDERSON R, TINTINGER G R, FELDMAN C. Inflammation and cancer: The role of the human neutrophil [J]. South African Journal of Science, 2014, 110(1/2): 1-6.
[18] BENCSIKOVá B, GREPLOVá K, PILáTOVá K, et al. [Platelets in the pathogenesis of solid tumors] [J]. Casopis lekaru ceskych, 2014, 153(2): 78-85.
[19] EL HOUAT Y, MASSARD C, QUILLIEN V, et al. Meta-analysis and Critical Review: Association Between Radio-induced Lymphopenia and Overall Survival in Solid Cancers [J]. Advances in radiation oncology, 2023, 8(2): 101038.
[20] LI C, WU J, JIANG L, et al. The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center study [J]. Cancer Immunology, Immunotherapy, 2022, 72(3): 783-794.
[21] RECK M, SCHENKER M, LEE K H, et al. Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial [J]. European journal of cancer (Oxford, England : 1990), 2019, 116: 137-147.
[22] HERBST R S, GIACCONE G, DE MARINIS F, et al. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC [J]. The New England journal of medicine, 2020, 383(14): 1328-1339. 

Downloads: 533
Visits: 33289

Sponsors, Associates, and Links


All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.